湿性年龄相关性黄斑变性的治疗进展  

Recent advances in treatment of wet age-related macular degeneration

作　　者：李铭[1] 魏伟[2] 

机构地区：[1]南京中医药大学,中国江苏省南京市210000 [2]江苏省中医院眼科,中国江苏省南京市210000

出　　处：《国际眼科杂志》2015年第2期251-254,共4页International Eye Science

摘　　要：年龄相关性黄斑变性(age-related macular degeneration,AMD)是WHO现阶段三大防盲重点眼病之一,是50岁以上人群主要的致盲眼病之一,65岁以上的人群中,约2%因患本病而导致单眼失明,随着人口老龄化,我国AMD的患病率也在增加。AMD就其临床表现分为干性AMD和湿性AMD,湿性AMD对患者的视力危害最大,目前AMD的治疗很多(主要是针对湿性AMD),主要包括激光治疗、药物治疗、手术治疗、基因治疗等,以下对近年来湿性AMD的治疗作一综述。Age-related macular degeneration （ AMD ） is one of the important eye diseases of the WHO present three big blindness, is one of the main blinding eye disease in people over the age of 50, people over the age of 65, about 2% of the disease caused by monocular blindness, as the population ages, AMD prevalence is increasing in our country. AMD with respect to its clinical manifestations can be divided into dry AMD and wet AMD, wet AMD is the most harmful for the vision of patients, at present there are many treatments for AMD （ mainly for wet age-related macular degeneration ） , mainly including laser treatment, drug therapy, surgical treatment, gene therapy, etc. The treatments of AMD would be illuminated in this article.

关 键 词：湿性年龄相关性黄斑变性 抗血管内皮生长因子治疗 基因治疗 

分 类 号：R774.5[医药卫生—眼科]